Oliver Sexton: Investment Director

Oliver Sexton

Oliver Sexton joined Midven in April 2014 to manage the UK Innovation & Science Seed Fund’s synthetic biology investments.

Prior to joining Midven, Oliver managed commercialisation of bioengineering and medical technologies At Imperial Innovations and was on the board of oncology therapeutic Acublate Ltd. Earlier in his career he held commercial and partnering roles at Ark Therapeutics.

Oliver also managed a team of biotech buy-side analysts and worked at a pharma strategy consultancy.

Oliver has a BSc in Molecular Biology/Biotechnology and an MSc in Plant Science from Bristol University.

Telephone 0121 710 1990

“Turning world-leading research into profitable companies is no simple matter, but we are now at a point where many of those technologies are suitable for broad commercial application. UK Innovation & Science Seed Fund is providing not just capital, but the expertise and the networks to maximize the chances of success in existing markets and in the new markets that synthetic biology enables.”


Oliver Sexton

Associated Companies

Relevant News

Rapid test for gonorrhoea and chlamydia to be developed by University of Birmingham spinout

25 November 2019: University of Birmingham spinout Linear Diagnostics Ltd has raised £2m to develop…

read more

CytoSeek Wins at Launch: Great West Rising Star Award

© Giulia Spadafora / Soul Media UKI2S would like to congratulate CytoSeek on winning the…

read more

Former Quethera leadership wins BVCA Management Team Award

14th June 2019 / UKI2S, a leading early-stage venture capital fund facilitating the growth of…

read more

Astellas Announces Acquisition of Quethera

Acquisition furthers Astellas’ commitment to innovation in ophthalmology with addition of novel gene therapy program…

read more

Scientists scramble to stop bananas being killed off

Banana plantations in Australia, south-east Asia, Africa and the Middle East have been ravaged by…

read more

Case Studies

Case Study - Synthace

Synthace London-based Synthace provides next-generation software and processes to exponentially improve productivity in bioscience, enabling…

read more


A Fork in the Road: Quethera’s Story

UKI2S announced in August the successful exit of its portfolio company Quethera. Acquired by Japanese…

read more

A Discussion with UK Innovation & Science Seed Fund’s Oliver Sexton

Oliver Sexton, MSc, is Midven’s investment director and manager of UK Innovation & Science Seed…

read more

Today’s Academic Projects Are Becoming Tomorrow’s Billion Pound Companies

  When we talk about the tech revolution that is currently sweeping the industrialised world,…

read more

Other Team Members